- Home
- BGI vs ANEB Comparison
BGI vs ANEB Comparison
Compare BGI & ANEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BGI
- ANEB
- Stock Information
- Founded
- BGI 1879
- ANEB 2020
- Country
- BGI Canada
- ANEB United States
- Employees
- BGI N/A
- ANEB N/A
- Industry
- BGI
- ANEB Biotechnology: Pharmaceutical Preparations
- Sector
- BGI
- ANEB Health Care
- Exchange
- BGI Nasdaq
- ANEB Nasdaq
- Market Cap
- BGI 41.6M
- ANEB 36.7M
- IPO Year
- BGI 2005
- ANEB 2021
- Fundamental
- Price
- BGI $1.59
- ANEB $1.46
- Analyst Decision
- BGI
- ANEB Buy
- Analyst Count
- BGI 0
- ANEB 1
- Target Price
- BGI N/A
- ANEB $8.00
- AVG Volume (30 Days)
- BGI 33.7K
- ANEB 6.3K
- Earning Date
- BGI 12-03-2024
- ANEB 11-13-2024
- Dividend Yield
- BGI N/A
- ANEB N/A
- EPS Growth
- BGI N/A
- ANEB N/A
- EPS
- BGI N/A
- ANEB N/A
- Revenue
- BGI $136,823,177.00
- ANEB N/A
- Revenue This Year
- BGI N/A
- ANEB N/A
- Revenue Next Year
- BGI N/A
- ANEB N/A
- P/E Ratio
- BGI N/A
- ANEB N/A
- Revenue Growth
- BGI 13.70
- ANEB N/A
- 52 Week Low
- BGI $1.53
- ANEB $1.25
- 52 Week High
- BGI $4.88
- ANEB $3.30
- Technical
- Relative Strength Index (RSI)
- BGI 11.98
- ANEB 36.57
- Support Level
- BGI $1.53
- ANEB $1.25
- Resistance Level
- BGI $2.19
- ANEB $1.68
- Average True Range (ATR)
- BGI 0.16
- ANEB 0.16
- MACD
- BGI -0.05
- ANEB -0.01
- Stochastic Oscillator
- BGI 8.21
- ANEB 30.00
About BGI Birks Group Inc.
Birks Group Inc is a part of the leisure industry. The company designs, develops, produces, and retails fine jewelry, timepieces, and gifts. Its operating segments include Retail and Other. The company generates maximum revenue from the Retail segment. Its retail segment consists of retail operations whereby it operates stores in Canada under the Maison Birks, Brinkhaus, Graff, and Patek Phillippe brands. The other segment consists mainly of wholesale business, e-commerce business, and gold exchange business.
About ANEB Anebulo Pharmaceuticals Inc.
Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company, developing novel solutions for people suffering from cannabinoid overdose and substance addiction. The product candidate, ANEB-001, is intended to reverse the negative effects of cannabinoid overdose within 1 hour of administration. The signs and symptoms of cannabinoid overdose range from profound sedation to anxiety and panic to psychosis with hallucinations.